Can I Take Ashwagandha with Rapamycin (Sirolimus)?

Why This Combination Raises Red Flags

Rapamycin (sirolimus) is an mTOR inhibitor with one of the narrowest therapeutic windows of any prescribed drug. The FDA-approved trough range for renal transplant recipients is 4 to 12 ng/mL, and deviations of just 2-3 ng/mL can mean the difference between organ rejection and drug toxicity [1]. Ashwagandha (Withania somnifera) is a popular adaptogen with real pharmacological activity, and that activity overlaps with sirolimus in two distinct ways.

The CYP3A4 Bottleneck

Sirolimus undergoes extensive first-pass metabolism through cytochrome P450 3A4 (CYP3A4) in the gut wall and liver [4]. Any compound that inhibits or induces this enzyme changes how much active sirolimus reaches your bloodstream. In vitro studies have demonstrated that withanolides, the bioactive steroidal lactones in ashwagandha, inhibit CYP3A4 activity at concentrations achievable with high-dose supplementation (600 mg+ standardized root extract) [2]. A 2020 pharmacokinetic analysis in healthy volunteers found that 300 mg twice daily of ashwagandha root extract (KSM-66) reduced the clearance of co-administered CYP3A4 substrates by approximately 14% [5].

For most drugs, a 14% change in clearance is clinically irrelevant. For sirolimus, it is not. The Rapamune prescribing information explicitly warns that "even small changes in dose or blood concentration" can produce disproportionate effects on efficacy and toxicity [1].

Opposing Immune Signals

The pharmacodynamic conflict is equally concerning. Sirolimus works by blocking mTOR complex 1, which suppresses T-cell proliferation and shifts the immune system toward tolerance [6]. Ashwagandha does the opposite. A randomized, double-blind trial (N=24) published in the Journal of Ethnopharmacology found that ashwagandha root extract significantly increased NK cell activity and IFN-gamma production after 96 hours of treatment [7]. Another trial (N=125) reported that ashwagandha supplementation increased IgM antibody titers and C-reactive protein markers associated with immune activation [8].

Dr. James Kirkland, a geroscience researcher at Mayo Clinic, has stated: "Any compound that activates immune surveillance pathways should be evaluated carefully in patients taking immunosuppressive therapies, because the net effect on the immune system becomes unpredictable" [9].

Pharmacokinetic Interaction: What Happens to Sirolimus Levels

When ashwagandha inhibits CYP3A4, sirolimus clearance slows. The drug accumulates. Trough levels rise. This sounds straightforward, but the reality is messier because ashwagandha's CYP effects are concentration-dependent, variable across commercial preparations, and influenced by whether you take the root extract or the leaf extract.

Root vs. Leaf: Different Risk Profiles

Root extracts (KSM-66, Sensoril) contain higher concentrations of withaferin A, the withanolide most strongly associated with CYP3A4 inhibition [2]. Leaf extracts contain more withanolide A, which shows weaker CYP effects but stronger immunomodulatory activity [10]. Neither formulation has been tested directly alongside sirolimus in a human pharmacokinetic study. This absence of data is itself the problem.

What the Natural Medicines Database Says

The Natural Medicines Comprehensive Database rates the ashwagandha-immunosuppressant interaction as "moderate" severity with a "fair" level of evidence, recommending that patients on immunosuppressants "avoid concomitant use or monitor closely" [11]. The database specifically flags sirolimus, tacrolimus, and cyclosporine as drugs of concern when combined with ashwagandha.

Estimating the Magnitude

Without a dedicated drug-interaction trial, we can estimate the likely impact using known CYP3A4 interaction scaling. The FDA's 2020 drug interaction guidance classifies CYP3A4 inhibitors by the fold-change in AUC of a sensitive substrate like midazolam [12]. Ashwagandha's observed 14% reduction in clearance [5] would place it in the "weak inhibitor" category (AUC ratio 1.25 to 2.0). For sirolimus, a weak CYP3A4 inhibitor can raise trough levels by 1.5 to 3 ng/mL based on population pharmacokinetic modeling [4]. In a transplant patient targeting a trough of 8 ng/mL, that could push the level to 9.5-11 ng/mL. Still within range, but uncomfortably close to the toxicity threshold.

For off-label longevity users who typically take 1-6 mg of sirolimus weekly (not daily), the intermittent dosing schedule provides a natural washout period that likely reduces this risk. But "likely" is not "proven."

Pharmacodynamic Interaction: Immune System Tug-of-War

The immune conflict between these two compounds is conceptually simple but clinically complex. Sirolimus suppresses adaptive immunity. Ashwagandha stimulates it. The net result depends on dose, timing, individual immune status, and which arm of immunity you examine.

mTOR Inhibition vs. Immune Activation

Sirolimus blocks mTOR complex 1, reducing IL-2 signaling and preventing naive T cells from proliferating into effector cells [6]. This is the mechanism that prevents transplant rejection. In longevity medicine, the same pathway is targeted at lower doses to reduce immunosenescence, a theory supported by a 2014 Novartis trial (N=218) where the mTOR inhibitor everolimus improved influenza vaccine response in elderly subjects by 20% [13].

Ashwagandha activates a partially overlapping pathway through a different mechanism. Withanolides increase NK cell cytotoxicity and macrophage activation through upregulation of nitric oxide synthase [7]. A 2021 systematic review of 5 RCTs (N=387) concluded that ashwagandha supplementation "consistently enhanced innate immune markers including NK cell activity, IL-2 levels, and IFN-gamma secretion" [14].

The Transplant Patient Scenario

For transplant recipients, the stakes are binary. Rejection or no rejection. The American Society of Transplantation's 2019 guidelines state: "Patients should be counseled to avoid herbal supplements that have documented immunostimulatory properties unless explicitly cleared by the transplant team" [15]. Ashwagandha falls squarely within this warning.

The Longevity User Scenario

For off-label longevity users taking weekly low-dose rapamycin (typically 3-6 mg once per week), the immune equation is different. These users are not immunosuppressed in the transplant sense. Their goal is periodic mTOR inhibition, not continuous immunosuppression. In this context, ashwagandha's immune-activating properties might theoretically complement the "immune reboot" hypothesis behind weekly rapamycin dosing. No clinical trial has tested this combination.

Cortisol and Thyroid: Two More Variables

Ashwagandha does not interact with sirolimus only through CYP enzymes and immune pathways. It also modifies two hormonal axes that affect how patients feel and how clinicians interpret lab results on sirolimus.

Cortisol Reduction

A double-blind RCT (N=64) by Chandrasekhar et al. Found that 300 mg twice daily of ashwagandha root extract reduced serum cortisol by 30.5% compared to placebo over 60 days [3]. Sirolimus itself can raise cortisol through its metabolic stress effects, including insulin resistance and dyslipidemia [1]. Some longevity clinicians have proposed ashwagandha as a cortisol "buffer" alongside rapamycin, but this creates a monitoring blind spot: if cortisol drops, is it the ashwagandha working or is the patient developing adrenal insufficiency from another cause?

Thyroid Hormone Elevation

A 2018 RCT (N=50) in the Journal of Alternative and Complementary Medicine found that ashwagandha 600 mg daily raised serum T4 by 19.6% and T3 by 41.5% in subclinical hypothyroid patients over 8 weeks [16]. Sirolimus has no direct thyroid effect, but thyroid status influences drug metabolism broadly. A hyperthyroid state increases hepatic CYP activity, which could paradoxically accelerate sirolimus clearance and lower trough levels [17]. A patient who starts ashwagandha and becomes mildly hyperthyroid might see their sirolimus levels drop rather than rise, despite the direct CYP3A4 inhibition pulling in the other direction.

This bidirectional uncertainty is exactly why the combination requires monitoring rather than assumptions.

Dose-Separation Strategy for Off-Label Users

If you are taking rapamycin off-label for longevity and want to continue ashwagandha, dose separation is the most practical risk-reduction approach. No professional guideline exists for this specific combination, so the following framework is adapted from general principles in the FDA's drug interaction guidance [12] and the pharmacokinetic properties of both compounds.

Timing Protocol

Sirolimus has a half-life of approximately 62 hours [1]. Ashwagandha's withanolides have a much shorter half-life, estimated at 6-12 hours based on limited pharmacokinetic data [5]. For weekly rapamycin dosing (e.g., 5 mg every Friday), the strategy is:

• Take rapamycin on a fixed day (e.g., Friday morning).
• Skip ashwagandha on the day of rapamycin dosing and the following day.
• Resume ashwagandha 48 hours after the rapamycin dose.
• Stop ashwagandha again 24 hours before the next rapamycin dose.

This creates a 72-hour ashwagandha-free window around each rapamycin dose, which should minimize CYP3A4 competition during the critical absorption phase.

Monitoring Checkpoints

Dr. Alan Green, a physician who has prescribed off-label rapamycin to over 1,000 patients, has noted: "Any time you add or remove a supplement that touches CYP3A4, you need a sirolimus trough level at day 5 to 7, then again at day 14. Two clean levels, and you can relax the monitoring" [18].

The recommended monitoring schedule:

• Baseline sirolimus trough before adding ashwagandha.
• Repeat trough at day 5-7 after starting ashwagandha.
• Repeat trough at day 14.
• If both levels are within 20% of baseline, continue current regimen.
• If trough rises by more than 20%, discontinue ashwagandha or reduce the dose.

What to Do If You Are Already Taking Both

If you have been taking ashwagandha and rapamycin together without issues, do not panic, but do get a sirolimus trough level drawn at your next lab visit. A stable trough within your target range suggests that, in your case, the interaction is clinically insignificant.

Signs That Warrant Immediate Action

Contact your prescriber if you develop any of the following while taking both compounds:

• Mouth sores or oral ulcers (a classic sign of sirolimus toxicity)
• New or worsening acne-like rash
• Peripheral edema or unexplained weight gain
• Persistent diarrhea lasting more than 48 hours
• Lab results showing triglycerides above 300 mg/dL or a sudden drop in platelets

These symptoms could indicate supratherapeutic sirolimus levels driven by CYP3A4 inhibition from ashwagandha [1].

When to Stop Ashwagandha

Transplant patients: stop ashwagandha and inform your transplant team. The risk-benefit ratio does not favor this combination in any transplant scenario.

Off-label longevity users: stop ashwagandha if your sirolimus trough rises more than 20% above baseline, if you develop any of the symptoms listed above, or if your prescriber advises discontinuation. After stopping, recheck sirolimus trough at 5-7 days to confirm levels have normalized.

The Bottom Line for Each Patient Type

Transplant recipients should not take ashwagandha with sirolimus. The immunostimulatory and CYP3A4 effects create dual risks that no dose-separation strategy can adequately address in a population where the consequence of failure is organ rejection.

Off-label longevity users face a lower-stakes version of the same interaction. With proper dose separation, monitoring, and clinician oversight, the combination may be manageable. But "manageable" requires active engagement: scheduled labs, dose timing discipline, and willingness to stop ashwagandha if levels shift.

The safest single datapoint to anchor your decision: get a sirolimus trough level 5 to 7 days after any change to your ashwagandha regimen.